In 2019, WHO will ramp up work to eliminate cervical cancer worldwide by increasing coverage of the HPV vaccine, among other interventions.
New Year Resolutions: Ten health issues WHO will tackle this year
The United States Department of Health and Human Services (DHHS) recently updated its guidelines on the use of antiretroviral agents in pregnant women with HIV infection. Dolutegravir is newly listed as a preferred agent to initiate during the second and third trimester of pregnancy. However, the guidelines reiterate a conservative interim recommendation that dolutegravir not be initiated during the first trimester of pregnancy based on preliminary data from a study in Botswana raising concerns about a possible small increased risk of neural tube defects with maternal dolutegravir use around the time of conception. The recommendation will likely be clarified as further data become available. Our recommendations are generally consistent with these guidelines.Details
This biologic agent lacks the antibody Fc- region responsible for placental transfer of immunoglobulins.A recent analysis of the manufacturer’s pharmacovigilance database, representing the largest available cohort of exposed pregnant women (including over 300 women with rheumatic diseases and nearly 200 with Crohn disease), identified over 530 prospectively documented outcomes of maternal exposure. Over 80 percent…Details
1. This randomized controlled trial of women with metastatic triple-negative breast cancer reports that patients who were received atezolizumab with nab-paclitaxel had longer periods of progression-free survival compared to patients who received placebo plus nab-paclitaxel therapy.Details